Pacira’s Q3 EXPAREL® sales figure was slightly ahead of our expectations showing 5% growth on Q2 in what is typically a quiet quarter. We continue to expect the growth trajectory to increase in Q4 and for Skyepharma to receive an $8m sales milestone in 2016. We remain bullish on EXPAREL®’s long term growth potential with Pacira working on trials for nerve block, oral surgery and other indications. Discussions are still on-going with partners for EXPAREL® outside of the US. We continue to believe ....

28 Oct 2015
EXPAREL® Q3 sales slightly ahead of expectations

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
EXPAREL® Q3 sales slightly ahead of expectations
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
28 Oct 2015 -
Author:
Singer CM Team -
Pages:
3 -
Pacira’s Q3 EXPAREL® sales figure was slightly ahead of our expectations showing 5% growth on Q2 in what is typically a quiet quarter. We continue to expect the growth trajectory to increase in Q4 and for Skyepharma to receive an $8m sales milestone in 2016. We remain bullish on EXPAREL®’s long term growth potential with Pacira working on trials for nerve block, oral surgery and other indications. Discussions are still on-going with partners for EXPAREL® outside of the US. We continue to believe ....